Combination product jurisdiction
This article was originally published in The Gray Sheet
FDA's 1991 Intercenter Agreements "should not be independently relied upon," although they "may still be helpful in certain situations," OCP advises in a FDL-1jurisdictional update posted on its website Sept. 6. The ICAs provided some guidance for how combination products would be regulated based on the "way the world was in 1991," OCP Director Mark Kramer said, but his office is working to create processes that are "more translatable to the future." OCP recently issued guidance on writing a request for center designation, incorporating the agency's primary mode of action 1final rule. It also posted two concept papers Sept. 6...
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.